Terms: = Skin cancer AND LDH AND Staging
39 results:
1. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E; Nguyen VA; Koelblinger P; Wolf I; Kehrer H; Saxinger W; Ressler JM; Weinlich G; Meyersburg D; Hafner C; Jecel-Grill E; Kofler J; Lange-Asschenfeldt B; Weihsengruber F; Rappersberger K; Svastics N; Gasser K; Seeber A; Kratochvill F; Nagler S; Mraz B; Hoeller C
Melanoma Res; 2024 Apr; 34(2):142-151. PubMed ID: 38092013
[TBL] [Abstract] [Full Text] [Related]
2. staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
Allen PB; McCook-Veal AA; Switchenko JM; Paulino DM; Niyogusaba T; Baird KM; Tarabadkar ES; Lechowicz MJ
Cancer; 2023 Feb; 129(4):541-550. PubMed ID: 36523150
[TBL] [Abstract] [Full Text] [Related]
3. An analysis of lactate dehydrogenase (ldh) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability.
Desai AD; Chinta S; Yeh C; Shah VP; Shah R; Paskhover B; Schwartz RA
Arch Dermatol Res; 2023 May; 315(4):799-806. PubMed ID: 36318305
[TBL] [Abstract] [Full Text] [Related]
4. Clinical predictors of survival in real world practice in stage IV melanoma.
Hu HP; Archer C; Yip D; Peters G
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1691. PubMed ID: 36161287
[TBL] [Abstract] [Full Text] [Related]
5. Imaging and Laboratory Workup for Melanoma.
Kaleem A; Patel N; Chandra SR; Vijayaraghavan RL
Oral Maxillofac Surg Clin North Am; 2022 May; 34(2):235-250. PubMed ID: 35428504
[TBL] [Abstract] [Full Text] [Related]
6. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
[TBL] [Abstract] [Full Text] [Related]
7. External validation of the American Joint Committee on cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program.
Tjokrowidjaja A; Browne L; Soudy H
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e280-e288. PubMed ID: 34811927
[TBL] [Abstract] [Full Text] [Related]
8. Validation of the American Joint Committee on cancer Eighth Edition staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract] [Full Text] [Related]
9. The association between active tumor volume, total lesion glycolysis and levels of S-100B and ldh in stage IV melanoma patients.
Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
[TBL] [Abstract] [Full Text] [Related]
10. Lactate dehydrogenase in dermatology practice.
Livesey A; Garty F; Shipman AR; Shipman KE
Clin Exp Dermatol; 2020 Jul; 45(5):539-543. PubMed ID: 31755143
[TBL] [Abstract] [Full Text] [Related]
11. The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis.
Trippel A; Halling F; Heymann P; Ayna M; Al-Nawas B; Ziebart T
Oral Maxillofac Surg; 2019 Sep; 23(3):343-352. PubMed ID: 31093793
[TBL] [Abstract] [Full Text] [Related]
12. Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients.
Cui C; Lian B; Zhou L; Song X; Zhang X; Wu D; Chi Z; Si L; Sheng X; Kong Y; Tang B; Mao L; Wang X; Li S; Dai J; Yan X; Bai X; Balch CM; Guo J
Ann Surg Oncol; 2018 Aug; 25(8):2184-2192. PubMed ID: 29748886
[TBL] [Abstract] [Full Text] [Related]
13. Melanoma staging: Evidence-based changes in the American Joint Committee on cancer eighth edition cancer staging manual.
Gershenwald JE; Scolyer RA; Hess KR; Sondak VK; Long GV; Ross MI; Lazar AJ; Faries MB; Kirkwood JM; McArthur GA; Haydu LE; Eggermont AMM; Flaherty KT; Balch CM; Thompson JF;
CA Cancer J Clin; 2017 Nov; 67(6):472-492. PubMed ID: 29028110
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
[TBL] [Abstract] [Full Text] [Related]
15. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
[TBL] [Abstract] [Full Text] [Related]
16. Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients.
Panasiti V; Curzio M; Roberti V; Lieto P; Devirgiliis V; Gobbi S; Naspi A; Coppola R; Lopez T; di Meo N; Gatti A; Trevisan G; Londei P; Calvieri S
Dermatology; 2013; 227(1):55-61. PubMed ID: 24008289
[TBL] [Abstract] [Full Text] [Related]
17. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
[TBL] [Abstract] [Full Text] [Related]
19. S-100B: a stronger prognostic biomarker than ldh in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract] [Full Text] [Related]
20. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract] [Full Text] [Related]
[Next]
